BioMarin Pharmaceutical (MEX:BMRN) Cyclically Adjusted FCF per Share: MXN6.97 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:BMRN BioMarin Pharmaceutical Inc MEX:BMRN
80 GF Score
Price MXN959.00
GF Value MXN1,420.64
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is BioMarin Pharmaceutical Cyclically Adjusted FCF per Share?

BioMarin Pharmaceutical MEX:BMRN 80 Cyclically Adjusted FCF per Share is MXN6.97 as of Mar. 2026. GuruFocus rates MEX:BMRN with a GF Score™ of 80/100 and a GF Value™ of MXN1,420.64 (Significantly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

BioMarin Pharmaceutical's adjusted free cash flow per share for the three months ended in Mar. 2026 was MXN18.220. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is MXN6.97 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of BioMarin Pharmaceutical was 17.00% per year. The lowest was -15.00% per year. And the median was 2.85% per year.

As of today (2026-07-18), BioMarin Pharmaceutical's current stock price is MXN959.00. BioMarin Pharmaceutical's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was MXN6.97. BioMarin Pharmaceutical's Cyclically Adjusted Price-to-FCF of today is 137.59.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of BioMarin Pharmaceutical was 582.55. The lowest was 129.53. And the median was 147.80.


BioMarin Pharmaceutical  (MEX:BMRN) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

BioMarin Pharmaceutical's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=959.00/6.97
=137.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of BioMarin Pharmaceutical was 582.55. The lowest was 129.53. And the median was 147.80.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


BioMarin Pharmaceutical Cyclically Adjusted FCF per Share Related Terms


BioMarin Pharmaceutical Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for BioMarin Pharmaceutical's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioMarin Pharmaceutical Cyclically Adjusted FCF per Share Chart

BioMarin Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -22.97 -22.87 -14.40 -16.29 1.81

BioMarin Pharmaceutical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.37 -5.39 -1.10 1.81 6.97

MEX:BMRN vs CYTK, ARWR, TECH: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, BioMarin Pharmaceutical's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioMarin Pharmaceutical Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioMarin Pharmaceutical's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where BioMarin Pharmaceutical's Cyclically Adjusted Price-to-FCF falls into.


MEX:BMRN
80GF Score
BioMarin Pharmaceutical Inc MEX:BMRN
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioMarin Pharmaceutical Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BioMarin Pharmaceutical's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=18.22/330.2130*330.2130
=18.220

Current CPI (Mar. 2026) = 330.2130.

BioMarin Pharmaceutical Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -8.111 241.018 -11.113
201609 -4.204 241.428 -5.750
201612 -6.199 241.432 -8.479
201703 -16.302 243.801 -22.080
201706 -3.004 244.955 -4.050
201709 -0.434 246.819 -0.581
201712 -2.829 246.524 -3.789
201803 -7.495 249.554 -9.917
201806 -6.263 251.989 -8.207
201809 -0.280 252.439 -0.366
201812 0.801 251.233 1.053
201903 -9.285 254.202 -12.061
201906 -6.548 256.143 -8.442
201909 3.686 256.759 4.740
201912 -0.368 256.974 -0.473
202003 -7.418 258.115 -9.490
202006 -0.734 257.797 -0.940
202009 7.382 260.280 9.365
202012 -5.825 260.474 -7.385
202103 9.453 264.877 11.785
202106 6.069 271.696 7.376
202109 8.608 274.310 10.362
202112 -3.708 278.802 -4.392
202203 -7.776 287.504 -8.931
202206 3.026 296.311 3.372
202209 13.206 296.808 14.692
202212 -3.099 296.797 -3.448
202303 -9.153 301.836 -10.014
202306 4.161 305.109 4.503
202309 10.226 307.789 10.971
202312 -0.830 306.746 -0.893
202403 1.072 312.332 1.133
202406 8.856 314.175 9.308
202409 20.006 315.301 20.952
202412 17.522 315.605 18.333
202503 16.413 319.799 16.947
202506 16.041 322.561 16.422
202509 31.995 324.800 32.528
202512 5.120 324.054 5.217
202603 18.220 330.213 18.220

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of MXN6.97 mean?
BioMarin Pharmaceutical (MEX:BMRN) has a Cyclically Adjusted FCF per Share of MXN6.97 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on BioMarin Pharmaceutical and its competitors.
Is BioMarin Pharmaceutical's Cyclically Adjusted FCF per Share too high?
BioMarin Pharmaceutical's current Cyclically Adjusted FCF per Share is MXN6.97. Overall, BioMarin Pharmaceutical has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's Cyclically Adjusted FCF per Share compare to CYTK and ARWR?
BioMarin Pharmaceutical's Cyclically Adjusted FCF per Share of MXN6.97 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on BioMarin Pharmaceutical and its competitors. BioMarin Pharmaceutical's current Cyclically Adjusted FCF per Share is MXN6.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, BioMarin Pharmaceutical (MEX:BMRN) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,420.64, compared to a current price of MXN959.00 — trading 32.5% below its estimated fair value. The current Cyclically Adjusted FCF per Share is MXN6.97. BioMarin Pharmaceutical's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For BioMarin Pharmaceutical (MEX:BMRN), the current Cyclically Adjusted FCF per Share is MXN6.97 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioMarin Pharmaceutical (MEX:BMRN) Overvalued in 2026?

Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued. The current stock price of MXN959.00 is trading 32.5% below its estimated GF Value™ of MXN1,420.64. GuruFocus considers BioMarin Pharmaceutical to be Significantly Undervalued.

Key valuation signals for MEX:BMRN:

  • Cyclically Adjusted FCF per Share: MXN6.97
  • GF Value™: MXN1,420.64 vs. price of MXN959.00 (32.5% below fair value)
  • GF Score™: 80/100 with 3 warning signs

No single metric tells the full story. See the MEX:BMRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioMarin Pharmaceutical Business Description

Address 770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
80GF Score

Get the complete analysis for MEX:BMRN

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN959.00
Price
MXN1,420.64
GF Value